期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

吉非替尼治疗晚期女性肺腺癌的临床观察 被引量：2

下载PDF
导出
摘要 目的：了解吉非替尼在治疗晚期女性肺腺癌的疗效、生活质量、存活期和不良反应.方法：对33例女性晚期肺腺癌给予吉非替尼250 mg/d治疗,直至患者肿瘤进展、死亡或出现不可耐受的不良反应.结果：33例患者均可评价,总有效率（ORR）66.7%（95% CI 56.53%～76.87%）,疾病控制率78.8%（95% CI 63.58%～84.02%）;PFS 9.3个月（1～37个月）,中位生存期11.2个月（1～42个月）,1年生存率54.54%（18/33）,2年生存率12.1%（4/33）.结论：吉非替尼治疗女性晚期肺腺癌有较满意的疗效、存活率和生活质量.
作者 吴江 袁志敏 林晓辉 庞世权 余海青
机构地区 广东省深圳市宝安人民医院肿瘤内科
出处 《吉林医学》 CAS 2012年第5期948-949,共2页 Jilin Medical Journal
关键词 肺腺癌 吉非替尼 靶向治疗
分类号 R734.2 [医药卫生—肿瘤]
  • 相关文献

参考文献3

  • 1梁国木梁,李进,马军.中国临床肿瘤学教育专辑(2008)[M].北京:中国协和医科大学出版社,2008:92-100.
  • 2管忠震,张力,李龙芸,蒋国梁,刘叙仪,储大同,赵洪云,李玮.吉非替尼治疗局部晚期或转移性非小细胞肺癌在中国的临床研究[J].癌症,2005,24(8):980-984. 被引量：114
  • 3Kimmura H,Kasahara K,Shibata K,et al.EGFR mutation of tumor and serum in gefitinib-treated patients with chemotherapy in non-small cell lung cancer[J].Thorac Oncol,2006,1(3):260.

二级参考文献12

  • 1潘振奎,张力,张星,王欣,李宁,徐菲,常建华,管忠震.中国非小细胞肺癌患者表皮生长因子受体突变的研究[J].癌症,2005,24(8):919-923. 被引量：44
  • 2Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors [J]. J Natl Cancer Inst, 2000,92(3) :205-216.
  • 3Kosmidis P. Chemotherapy in NSCLC: histrocial review [J].Lung Cancer, 2002,38(Suppl 3):S19-S22.
  • 4Shepherd FA, Dancey J, Ramlau R, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy [J]. J Clin Oncol, 2000,18(10): 2095-2103.
  • 5Fossella DV, DeVore R, Kerr RN, et al. Randomized phase Ⅲ trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previous treated with platinum-containing chemotherapy regimens [J]. J Clin Oncol,2000,18(12) :2354-2362.
  • 6Fukuoka M, Yano S, Giaccone G, et al. Multi-institutional randomized phase Ⅱ trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer [J]. J Clin Oncol, 2003,21 (12): 2237-2246.
  • 7Kris MG, Natale RB, Herbst RS, et al. Efficacy of gefitinib,an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer [J]. JAMA, 2003,290(16) :2149-2158.
  • 8Lynch, T, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying resensiveness of non-small-cell lung cancer to gefitinib [J]. N Engl J Med,2004,350(21 ): 2129-2139.
  • 9Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy [J]. Science, 2004,304(5676): 1497-1500.
  • 10Huang SF, Liu HP, Li LH, et al. High frequency of epidermal growth factor receptor mutations with complex patterns in nonsmall cell lung cancers related to gefitinib responsiveness in Taiwan [J]. Clin Cancer Res, 2004, 10(24) :8195-8203.

共引文献113

同被引文献34

  • 1柴红,陈泽泉,余永利.甲状腺髓样癌靶向治疗新进展[J].上海交通大学学报（医学版）,2011,31(10):1470-1474. 被引量：3
  • 2张冠中.培美曲塞与吉非替尼对人结肠癌细胞株作用的研究[D].中国人民解放军军医进修学院2011
  • 3Zhi Xiao,Nianhua Ding,Guiqing Xiao,Shouman Wang,Yuhui Wu,Lili Tang.Reversal of Multidrug Resistance by Gefitinib Via RAF1/ERK Pathway in Pancreatic Cancer Cell Line[J]. Anat Rec . 2012 (12)
  • 4David Adelstein,Cristina Rodriguez,Lisa Rybicki,Denise Ives,Thomas Rice.A phase II trial of gefitinib for recurrent or metastatic cancer of the esophagus or gastroesophageal junction[J]. Investigational New Drugs . 2012 (4)
  • 5Alessandro Antonelli,Poupak Fallahi,Silvia M. Ferrari,Ilaria Ruffilli,Francesca Santini,Michele Minuto,David Galleri,Paolo Miccoli.New Targeted Therapies for Thyroid Cancer[J]. Current Genomics . 2011 (8)
  • 6C. Gridelli,F. De Marinis,M. Di Maio,D. Cortinovis,F. Cappuzzo,T. Mok.Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating epidermal growth factor receptor mutation: Review of the evidence[J]. Lung Cancer . 2010 (3)
  • 7EleanorGutteridge,AmitAgrawal,RobertNicholson,KwokLeung Cheung,JohnRobertson,JuliaGee.The effects of gefitinib in tamoxifen‐resistant and hormone‐insensitive breast cancer: A phase II study[J]. Int. J. Cancer . 2010 (8)
  • 8Vuky Jacqueline,Porter Christopher,Isacson Christina,Vaughan Matthew,Kozlowski Paul,Picozzi Vincent,Corman John.Phase II trial of neoadjuvant docetaxel and gefitinib followed by radical prostatectomy in patients with high-risk, locally advanced prostate cancer. Cancer . 2009
  • 9Ohta Tsuyoshi,Ohmichi Masahide,Shibuya Tae,Takahashi Toshifumi,Tsutsumi Seiji,Takahashi Kazuhiro,Kurachi Hirohisa.Gefitinib (ZD1839) increases the efficacy of cisplatin in ovarian cancer cells. Cancer biology & therapy . 2012
  • 10S. Carloni,F. Fabbri,G. Brigliadori,P. Ulivi,R. Silvestrini,D. Amadori,W. Zoli.Tyrosine Kinase Inhibitors Gefitinib, Lapatinib and Sorafenib Induce Rapid Functional Alterations in Breast Cancer Cells. Current Cancer Drug Targets . 2010

引证文献2

二级引证文献10

吉林医学
2012年 第5期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部